Recent press releases

2 August 2004

Lectus Therapeutics announces chemistry collaboration with Evotec OAI

Lectus Therapeutics Limited (Lectus; www.lectustherapeutics.com), an emerging UK-based bio-pharmaceutical company focused on the discovery and development of next-generation ion channel modulators, announced today that it had entered into a chemistry collaboration with Evotec OAI (Frankfurt Stock Exchange: EVT, TecDAX 30). Under the terms of the agreement, Evotec OAI will supply Lectus with medicinal chemistry resources to advance its core ion channel drug discovery and development programmes in urinary bladder disorders, angina and hypertension.

Lectus identifies next-generation ion channel modulators by exploiting the power of its proprietary functional proteomics platform, LEPTICSTM (Leveraged Enabling Proteomics Technology for Ion Channel Screening). Development of next-generation ion channel modulators are expected to offer an enhanced safety profile for the treatment of disorders related to smooth muscle hyperreactivity.

Evotec OAI (Hamburg, Germany and Oxford, UK) is established as the leading partner for integrated high-value-added drug discovery and development solutions for biotechnology and pharmaceutical companies. Through a comprehensive range of capabilities and innovative technology platforms that integrate world-class biology and chemistry capabilities the company offers services from assay development and screening through to compound optimisation and drug manufacturing services.

Roland Kozlowski, co-founder and CEO of Lectus commented, “The deal with Evotec will allow Lectus to rapidly accelerate its own discovery and development agenda and provides further endorsement for the strength and capabilities within Lectus, which following a recent investment by Takeda Research Investment, is now set to become a significant player in the sector. We were very pleased with Evotec OAI's business development team who handled the relationship with Lectus very professionally and quickly understood the needs of an emerging company. As a result they structured a tailored deal that fitted with our requirements whilst providing us with best in class resources to drive forward medicinal chemistry programmes for identification of next-generation ion channel modulators”

Dr Mark Ashton, President Drug Discovery Services of Evotec OAI added, "Evotec OAI was very impressed with both Lectus Therapeutics' technology, uniquely developed for identification of next-generation ion channel modulators, and the company's underpinning commercial strategy. We are pleased that they have chosen us as their partner to support them in producing compounds likely to have significant economic and clinical advantages over existing types of ion channel modulator."

 Download this press release

© Lectus Therapeutics Ltd. 2003–2009